

# House Bill 2536

Sponsored by Representative GRAYBER, Senator LIEBER; Senator FREDERICK (Pre-session filed.)

## SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**. The statement includes a measure digest written in compliance with applicable readability standards.

Digest: The Act bans health benefit plans from using step therapy for certain cancer drugs and treatments. (Flesch Readability Score: 63.6).

Prohibits health benefit plans from requiring step therapy prior to covering a prescription drug for the treatment of metastatic cancer and associated conditions.

## A BILL FOR AN ACT

1  
2 Relating to step therapy for metastatic cancer treatment.

3 **Be It Enacted by the People of the State of Oregon:**

4 **SECTION 1. Section 2 of this 2025 Act is added to and made a part of the Insurance Code.**

5 **SECTION 2. (1) As used in this section:**

6 (a) **“Advanced metastatic cancer” means cancer that has spread from the primary or**  
7 **original site to nearby tissues, lymph nodes or other parts of the body.**

8 (b) **“Associated conditions” means the symptoms or side effects associated with advanced**  
9 **metastatic cancer or its treatment, which, at the discretion of a health care provider, fur-**  
10 **ther jeopardize the health of a patient if left untreated.**

11 (c) **“Health benefit plan” has the meaning given that term in ORS 743B.005.**

12 (d) **“Step therapy” has the meaning given that term in ORS 743B.001.**

13 (2) **Notwithstanding ORS 743B.602, a health benefit plan that provides coverage for ad-**  
14 **vanced metastatic cancer and associated conditions may not require step therapy prior to**  
15 **providing coverage of a prescription drug approved by the United States Food and Drug Ad-**  
16 **ministration.**

17 (3) **This section applies to the use of a drug that is:**

18 (a) **Consistent with best practices for the treatment of advanced metastatic cancer or**  
19 **associated conditions; and**

20 (b) **Supported by peer-reviewed, evidence-based literature.**

21 (4) **This section is exempt from ORS 743A.001.**

22 **SECTION 3. Section 2 of this 2025 Act applies to health benefit plans issued, offered or**  
23 **renewed on or after January 1, 2026.**

24  

---

  
**NOTE:** Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted. New sections are in **boldfaced** type.